vTv Therapeutics Strengthens Balance Sheet for Phase 3
HIGH POINT, N.C., November 6, 2025 — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company developing innovative oral...
biopharma innovation
Advertisement
Immedica Submits NDS for Loargys® (pegzilarginase) in Canada
Stockholm, Sweden – October 31, 2025 — Immedica Pharma has announced that its New Drug Submission (NDS) for Loargys®...
Allosite Therapeutics Showcases Novel Integrin Therapies at ASN 2025
Miami, Florida – October 30, 2025 — Allosite Therapeutics, a biotechnology company pioneering allosteric integrin agonists for the treatment...
Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
FDA Grants Fast Track to AJ201 for Kennedy’s Disease Therapy
TAIPEI, Taiwan – October 23, 2025 AnnJi Pharmaceutical Co., Ltd. (AJ Pharm) announced that the U.S. Food and Drug...
Advertisements
Visionary Holdings Launches Stem Cell Venture for Diabetes Cure
Toronto, Canada – October 22, 2025 — Visionary Holdings Inc., a global education and technology enterprise, announced the launch...
FDA Approves TEZSPIRE for Chronic Rhinosinusitis with Nasal Polyps
THOUSAND OAKS, Calif., October 17, 2025 — In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA)...
Celltrion Gains FDA Nod for YUFLYMA Pediatric Use Expansion
Incheon, South Korea – October 16, 2025 – CelltrionUSA, a subsidiary of Celltrion Inc., announced that the U.S. Food...
Oncolytics Prepares Registration Trial in First-Line Pancreatic Cancer
SAN DIEGO, Sept. 29, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) today announced a key update on its plan...
Aspen Advances Parkinson’s Therapy with Commercial ANPD001 Formulation
SAN DIEGO, Sept. 25, 2025 (cGxP.wire) – Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced...
Advertisement
